Table 2

 Metastatic disease detected at pretreatment evaluations

AuthorYearTests usedMetastatic rate (%)
LFTs, liver function tests; CXR, chest x ray; CT, computed tomography; COMS, collaborative ocular melanoma study.
*Further imaging (CT/MRI) done if liver enzyme assays abnormal.
Wagoner191982LFTs, liver spleen scan2.47
Pach201986LFTs, CXR, liver scan or CT abdomen2.2
COMS62004LFTs, CXR*<1
This study2005PET/CT3.8